Biodel Inc. (ALBO) Expected to Announce Earnings of -$0.85 Per Share
Wall Street brokerages expect Biodel Inc. (NASDAQ:ALBO) to post earnings of ($0.85) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Biodel’s earnings, with the lowest EPS estimate coming in at ($1.00) and the highest estimate coming in at ($0.76). The company is expected to announce its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that Biodel will report full year earnings of ($3.69) per share for the current fiscal year, with EPS estimates ranging from ($4.09) to ($3.38). For the next financial year, analysts expect that the business will post earnings of ($3.43) per share, with EPS estimates ranging from ($4.60) to ($2.65). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Biodel.
Biodel (NASDAQ:ALBO) last announced its quarterly earnings data on Monday, August 21st. The biopharmaceutical company reported ($0.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.02).
ALBO has been the topic of a number of research reports. Needham & Company LLC initiated coverage on shares of Biodel in a report on Tuesday, July 18th. They set a “buy” rating and a $35.00 target price on the stock. Zacks Investment Research raised shares of Biodel from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Tuesday, July 11th. Wedbush reissued an “outperform” rating and set a $58.00 target price on shares of Biodel in a report on Monday, September 11th. Cowen and Company initiated coverage on shares of Biodel in a report on Wednesday, August 16th. They set an “outperform” rating on the stock. Finally, ValuEngine lowered shares of Biodel from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $40.33.
COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/07/biodel-inc-albo-expected-to-announce-earnings-of-0-85-per-share.html.
Shares of Biodel (ALBO) traded down 1.33% on Friday, hitting $22.21. 16,926 shares of the stock were exchanged. The company has a 50-day moving average price of $22.94 and a 200-day moving average price of $22.22. Biodel has a one year low of $14.00 and a one year high of $37.69. The firm’s market capitalization is $197.27 million.
An institutional investor recently raised its position in Biodel stock. Renaissance Technologies LLC increased its stake in shares of Biodel Inc. (NASDAQ:ALBO) by 0.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 149,632 shares of the biopharmaceutical company’s stock after acquiring an additional 794 shares during the quarter. Renaissance Technologies LLC’s holdings in Biodel were worth $3,591,000 at the end of the most recent quarter. Institutional investors and hedge funds own 27.36% of the company’s stock.
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.